Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label mass balance study of 14C-aticaprant in healthy adult men
NL-OMON51737Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of aticaprant in major depressive disorder (MDD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Pharmacokinetics, metabolism, and routes of excretion of aticaprant and its metabolites. Started Jan 2022; status: completed.
02
Drugs
aticaprant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON51737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51737.